1. ZEUS
Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either Endeavor ZES or available thin strut BMS. They were followed for 1 year.
Results
Primary outcome: MACE: 17.5% vs. 22.1%, p = 0.011
CV death: 7.6% vs. 8.3%, p = 0.65; MI: 2.9% vs. 8.1%, p < 0.001; TLR: 5.2% vs. 10.4%, p < 0.001
Definite stent thrombosis: 1.0% vs. 2.2%, p = 0.05; TIMI major/minor bleeding: 1.7% vs. 2.1%, p = 0.72
Conclusions
Among patients with uncertain ability to use DES with longer duration DAPT (median duration ~1 month), ZES was superior to BMS for clinical outcomes, including MI, stent thrombosis, and TLR
Data provide further evidence that shorter durations of DAPT may be feasible with DES in select patient populations
Valgimigli M, et al. J Am Coll Cardiol 2015;65:805-15